Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Chloroform | HCID 6212 | — |
| Reactant | Boron tribromide | HCID 25134 | — |
| Reactant | Sodium Bicarbonate | HCID 516892 | — |
| Reactant | HCID 15027948 | HCID 15027948 | — |
| Solvent | Dichloromethane | HCID 6344 | — |
| Product | HCID 15027935 | HCID 15027935 | — |
Reaction Steps
360 mg of 7-methoxy-2-{4-[4-(4-methylpyridin-2-yl)-piperazin-1-yl]-butyl}-2H-1,4-benzothiazine-3(4H)-one (see Example 19) prepared analogously to Example 1 were added to 5 ml of dichloromethane with exclusion of moisture. After cooling to -5° C., a solution of 0.73 g of boron tribromide in 1 ml of methylene chloride was added dropwise with stirring. Stirring was then continued for a further 30 minutes at room temperature. The reaction mixture was worked up by adding it with stirring to a mixture of ice and aqueous sodium hydrogen carbonate solution. 200 ml of chloroform were then added. The resulting organic solution was washed with water, dried over sodium sulfate, filtered and concentrated under reduced pressure. The title compound was obtained from the remaining residue by fractional column chromatography. The fractions containing the title compound were concentrated and treated with ether. 30 mg of 7-hydroxy-2-{4-[4-(4-methylpyridin-2-yl)-piperazin-1-yl]butyl}-2H-1,4-benzothiazine-3(4H)-one were obtained as white crystals having a melting point of 212° C.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US05332733 |
|---|
| Source dataset | uspto-grants-1994_07 |
|---|
| ORD ID | ord-d750b947d3eb4b6e909c3deceb37b51a |
|---|
| Source note | uspto-grants-1994_07 |
|---|